New York State Teachers Retirement System Sells 6,306 Shares of Elevance Health, Inc. $ELV

New York State Teachers Retirement System trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV) by 3.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 182,047 shares of the company’s stock after selling 6,306 shares during the quarter. New York State Teachers Retirement System’s holdings in Elevance Health were worth $63,817,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Delta Investment Management LLC lifted its position in shares of Elevance Health by 21.5% during the fourth quarter. Delta Investment Management LLC now owns 28,692 shares of the company’s stock valued at $10,058,000 after purchasing an additional 5,080 shares in the last quarter. Simplicity Wealth LLC grew its position in Elevance Health by 20.0% in the 4th quarter. Simplicity Wealth LLC now owns 1,220 shares of the company’s stock worth $428,000 after purchasing an additional 203 shares in the last quarter. Joel Isaacson & Co. LLC grew its position in Elevance Health by 45.1% in the 4th quarter. Joel Isaacson & Co. LLC now owns 2,561 shares of the company’s stock worth $898,000 after purchasing an additional 796 shares in the last quarter. Pekin Hardy Strauss Inc. increased its stake in Elevance Health by 448.0% in the 4th quarter. Pekin Hardy Strauss Inc. now owns 9,618 shares of the company’s stock valued at $3,372,000 after buying an additional 7,863 shares during the last quarter. Finally, Keybank National Association OH increased its stake in Elevance Health by 1.5% in the 4th quarter. Keybank National Association OH now owns 9,104 shares of the company’s stock valued at $3,191,000 after buying an additional 132 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Down 0.1%

ELV opened at $376.39 on Friday. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $424.24. The company has a market cap of $81.74 billion, a PE ratio of 16.01, a price-to-earnings-growth ratio of 2.25 and a beta of 0.49. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $310.69 and a 200 day moving average of $331.90.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is 29.26%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ELV. Robert W. Baird boosted their target price on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a research report on Tuesday, February 3rd. Guggenheim lifted their price target on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Citigroup raised Elevance Health to a “buy” rating in a research report on Wednesday. Finally, Sanford C. Bernstein upped their price objective on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research note on Friday, April 24th. Thirteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.